Isofol Medical

* Financials fairly in line * Entering the final stage of Phase 1b, Phase 2 expected by YE'26 * Fairly neutral share price reaction expected Financials fairly in line For Q2'26, net income was in line with expectations at SEK -16m (vs. ABGSCe at SEX ...

* Solid cost control * Slower-than-expected patient recruitment * Negative share price reaction expected Solid cost control Net income came in fairly in line with expectations at SEK -15m (vs. ABGSCe at SEX -14m and SEK -13m in Q4'25), with CF from operating...